Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kura OncologyKURA -4.63%28 Days Inventory is 218.72 as of Mar. 2026, which is 92% below its 10-year median of 2,644.65. GuruFocus rates KURA with a GF Score™ of 28/100. The stock has 7 warning signs investors should review. Among 638 Biotechnology companies, Kura Oncology ranks worse than 89.5% on this metric.
Days Inventory is also known as Days Sales of Inventory (DSI). Kura Oncology's Average Total Inventories for the
three
months ended in Mar. 2026 was $0.63 Mil. Kura Oncology's Cost of Goods Sold for the
three
months ended in Mar. 2026 was $0.26 Mil.
Hence, Kura Oncology's Days Inventory for the
three
months ended in Mar. 2026 was 218.72.
The historical rank and industry rank for Kura Oncology's Days Inventory or its related term are showing as below:
KURA'
s Days Inventory Range Over the Past 10 Years
Min: 874.89 Med: 2644.65 Max: 2644.65
Current: 874.89
During the past 12 years, Kura Oncology's highest Days Inventory was 2644.65. The lowest was 874.89. And the median was 2644.65.
KURA's Days Inventory is ranked worse than 89.5% of 638
companies
in the Biotechnology industry
Industry Median: 183.195
vs KURA: 874.89
Kura Oncology's Days Inventory
increased
from Mar. 2025 (0.00) to Mar. 2026 (218.72).
It might indicate that Kura Oncology's sales slowed down.
Warning Sign:
If a company builds up inventory, it may mean it is having difficulties selling its goods.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Kura Oncology's Inventory Turnover for the
three
months ended in Mar. 2026 was 0.42.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Kura Oncology's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 0.03.
Kura Oncology (NAS:KURA) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Kura Oncology's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Kura Oncology's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Kura Oncology Days Inventory Related Terms
Kura Oncology Days Inventory Historical Data
* Premium members only.
The historical data trend for Kura Oncology's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
KURA vs REPL, AVTX, SANA: Days Inventory Comparison
For the Biotechnology subindustry, Kura Oncology's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kura Oncology Days Inventory vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Kura Oncology's Days Inventory distribution charts can be found below:
* The bar in red indicates where Kura Oncology's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kura Oncology (KURA) has a Days Inventory of 218.72 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Kura Oncology and its competitors. This is 92% below median its historical median of 2,644.65. Over the past decade, Kura Oncology's Days Inventory has ranged from 874.89 to 2,644.65. According to the industry distribution chart, Kura Oncology ranks #571 out of 638 companies in the Biotechnology industry, placing it in the top 89.5%.
Is Kura Oncology's Days Inventory too high?
Kura Oncology's current Days Inventory of 218.72 is 92% below median its 10-year median of 2,644.65. Over the past 10 years, this metric has ranged from a low of 874.89 to a high of 2,644.65. The Biotechnology industry median Days Inventory is 183.20. Kura Oncology's value of 218.72 is 19.4% above this industry median. Based on the distribution chart, Kura Oncology ranks #571 out of 638 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Kura Oncology has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Kura Oncology's Days Inventory compare to REPL and AVTX?
According to the Biotechnology industry distribution chart, Kura Oncology ranks #571 out of 638 companies for Days Inventory. This places Kura Oncology in the lower half of its industry. The industry median Days Inventory is 183.20. Kura Oncology's value of 218.72 is 19.4% above this benchmark. Historically, Kura Oncology's own Days Inventory has ranged from 874.89 to 2,644.65 over the past decade. While the company's 10-year median is 2,644.65 vs. the industry median of 183.20, Kura Oncology has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Biotechnology company?
The median Days Inventory among Biotechnology companies is 183.20, based on 638 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kura Oncology's current Days Inventory of 218.72 is 19.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Kura Oncology and its competitors. For the Biotechnology industry, the median Days Inventory is 183.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kura Oncology's current Days Inventory is 218.72, which is 92% below median its own 10-year median of 2,644.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kura Oncology stock overvalued right now?
Kura Oncology (KURA) has a current Days Inventory of 218.72. The current Days Inventory is 218.72, which is 92% below median its 10-year median of 2,644.65 and 19.4% above the Biotechnology industry median of 183.20. Kura Oncology's overall GF Score™ is 28/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Kura Oncology (KURA), the current Days Inventory is 218.72 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.
28GF Score
Get the complete analysis for KURA
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KURA has been successfully added to your 
